about
Metabolic profiling of patients with schizophreniaFirst do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment.Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.Metabolic syndrome in patients with severe mental illness in GorganPerinatal maternal undernutrition programs the offspring hypothalamo-pituitary-adrenal (HPA) axis.Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5'-monophosphate-activated protein kinase.Prevalence of metabolic syndrome among inpatients with schizophrenia.Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Metabolic syndrome: differences between psychiatric and internal medicine patients.Patient subpopulations with elevated cardiovascular risk pose unique treatment challenges.Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients.
P2860
Q33255317-549E582A-DA7A-4C5D-886F-017D3E9814ADQ33845881-DFA398EC-9301-4F0C-A8C2-64786E714B40Q35652340-73D0FAD2-A977-49BD-B095-879B7C56545AQ36375877-16AF0B97-0F85-4CCF-AAF8-77073C42C2FBQ36621075-6899DA52-CF18-4B9C-A346-59C5F8E7DE83Q36657453-467FEBDB-7BA5-4280-B899-FD486ED225D7Q36686813-65BBB743-06B4-41D6-8C44-FCD8CBEB166BQ37039179-EBB1E9AE-61D4-4C90-B4A2-72E8DBDD0AD4Q37079080-12D2F110-A449-488A-B3A9-8EADDBF4DF14Q44986103-34AB29FB-EA22-4140-B3FF-EDB13DFDB18BQ45974475-4BD4B02E-79CE-4028-A011-A68BCABBD821Q47569717-AD0FA852-40F1-4425-BC86-3FE91E22616AQ48229577-B2746412-1970-4C3E-A98A-E64BBAEA1D70Q48422028-D16A199A-438F-4AFF-BAE3-8DD736925602Q51910566-2F51A66B-FF2D-48B3-A679-0BAC7A571A0EQ54942497-F8107D7B-2495-45C1-83DC-7D3472F6C1AA
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The metabolic syndrome and schizophrenia: a review.
@ast
The metabolic syndrome and schizophrenia: a review.
@en
type
label
The metabolic syndrome and schizophrenia: a review.
@ast
The metabolic syndrome and schizophrenia: a review.
@en
prefLabel
The metabolic syndrome and schizophrenia: a review.
@ast
The metabolic syndrome and schizophrenia: a review.
@en
P2093
P2860
P1476
The metabolic syndrome and schizophrenia: a review.
@en
P2093
Carol E Koro
Gilbert J L'Italien
Jonathan Meyer
P2860
P304
P356
10.1080/09540260500071798
P577
2005-06-01T00:00:00Z